Clinical

The approval comes within months of avelumab being approved for the treatment of Merkel cell carcinoma.

Short-term use of high-flow nasal tubes can help patients experiencing exacerbations of their chronic obstructive pulmonary disease, according to a study in Respirology.

A colon cancer risk assessment study found that individuals who follow a healthy eating and exercise lifestyle reduce their likelihood of developing colorectal polyps or colorectal cancer.

Researchers have identified specific characteristics that can help identify responsiveness of patients with soft tissue sarcomas to immunotherapy.

Patients with irritable bowel syndrome with diarrhea (IBS-D) incur significantly more healthcare costs than matched controls. A new study in the Journal of Managed Care & Specialty Pharmacy found that the extra costs were associated with an increased use of medical services.

Midostaurin (Rydapt) has been approved by the FDA, in combination with chemotherapy, for the treatment of adult patients newly diagnosed with acute myeloid leukemia (AML) with a mutation in the FLT3 gene.

Is rubber meeting the road with big data in cancer care? “No…rather, not yet,” Green said at the 2017 Community Oncology Conference, April 26-27, held at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

Community oncologists believe that they are in a very good position to lead the way to achieve the goals of Cancer Moonshot.

At the 2017 Community Oncology Conference, participants discussed the impact of pharmacy benefit managers (PBMs) on oncology drug prices and patient access to much needed treatments.

The playing field regarding Medicare reimbursement and drug pricing has to be leveled between hospitals and community oncologists in order for physicians to compete for patients on the basis of the quality of care they provide,

The first drugs for nonalcoholic steatohepatitis (NASH) won't be approved until 2019 at the earliest, but with 16 million Americans affected and another 6 million to 10 million at high risk, the market could be expensive and it's worth keeping an eye on, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.

A study evaluating a patient-reported outcomes measure tool in patients who had undergone colorectal surgery recommends using the tool for preoperative counseling prior to surgery.

Eli Lilly and Company has announced that abemaciclib improved progression-free survival (PFS) when combined with an aromatase inhibitor (AI), compared with AI alone, in patients with breast cancer.